News & Events about Finch Therapeutics Group Inc.
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the Company, Finch, or Finch Therapeutics) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of ...
Globe Newswire
2 months ago
SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Finch or Finch Therapeutics) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today ...
Finch Therapeutics Group, Inc. (NASDAQ:FNCH Get Rating) traded down 3% on Friday . The company traded as low as $1.58 and last traded at $1.59. 11,318 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 344,381 shares. The stock had previously closed at $...
Globe Newswire
8 months ago
SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Finch or Finch Therapeutics) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today ...
Thinking about buying stock in Finch Therapeutics, Zymeworks, DiDi Global, Bilibili, or IQIYI? Thinking about buying stock in Finch Therapeutics, Zymeworks, DiDi Global, Bilibili, or IQIYI? PR Newswire NEW YORK, April 29, 2022 NEW YORK, April 29, 2022 /PRNewswire/ -- InvestorsObserverissues...